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Cardiovascular Actions of Lead and
Relationship to Hypertension: A Review
By Stephen J. Kopp,* John T. Barron,t and June P. Tow*
Chronic and acute lead poisoning cause overt, clinical symptoms of cardiac and vascular damage with
potentially lethal consequences. Morphological, biochemical, and functional derangements of the heart
have all been described in patients following exposure to excessive lead levels. Disturbances in cardiac
electrical and mechanical activity and postmortem evidence of morphological and biochemical derange-
ments of the myocardium have all been reported following excessive exposure to lead in humans. In
addition, signs of vascular degeneration, abnormal vascular smooth muscle function, and altered vessel
compliance have been described in humans chronically and acutely exposed to toxic lead levels. Similar
cardiovascular complications have been detected following excessive lead exposure in experimental
animals. Myocarditis, electrocardiographic disturbances, heightened catecholamine arrhythmogenicity,
altered myocardial contractile responsiveness to inotropic stimulation, degenerative structural and bio-
chemical changes affecting the musculature of the heart and vasculature, hypertension, hyper-
cholesterolemia, atherosclerosis, and increased vascular reactivity to a-adrenergic agonists have been
among the reported cardiovascular disturbances linked to lead poisoning. Less certain are the cardio-
vascular effects of subclinical lead poisoning. Although controversial, chronic low-level lead exposure
has been linked to hypertension and other cardiovascular disturbances in both clinical and experimental
studies. In general, it can be concluded that lead over a wide range of exposure intensities can induce
significant changes in the function of the cardiovascular system. Evidence points to the involvement of
multiple sites of action. Cardiac and vascular sites, as well as sites within the central nervous system,
have all been implicated in the sequelae of cardiovascular effects. The exact pathogenic mechanisms that
underlie the actions oflead in the cardiovascular system, however, have yet to be elucidated definitively.
Overview
Intense lead exposure has been linked since antiquity
to serious, sometimes lethal disturbances in cardiac
rhythmicity and contractile function. More subtle
effects have been reported following lead exposure at
lower levels; in some instances effects have been re-
ported at levels approaching those encountered pas-
sively in the general environment (1-6). These obser-
vations suggest that acute and chronic lead exposure
over a relatively broad dose range may be associated
with significant changes in the function of the car-
diovascular system. The severity of the reported effects
and the extent to which the cardiovascular system is
affected by lead appears to be influenced most directlyby
the dose of lead and the duration of lead exposure.
Other factors, such as route of exposure, age of the
individual, temperature, and dietary calcium intake
level, also appear to influence the expression and
severity of the cardiovascular symptoms manifested in
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response to both acute and chronic forms of lead expo-
sure (7).
For the most part, the interactive relationships
among these various factors have not been well-de-
lineated. The experimental findings that have been
reported suggest that lead acts at multiple sites within
the cardiovascular system. These findings include
direct effects on the excitability and contractility of the
heart (8-10), vascular sites of action affecting the
compliance and contractility of vascular smooth
muscle (11-15), and possibly sites of action within the
central nervous system affecting blood pressure regu-
lation(16-18). Although somewhat controversial,
there are also indications that chronic lead exposure
may affect systemic lipid metabolism. Elevated vascu-
lar lipid levels, vascular lipid infiltration, and in-
creased plaque deposition on arterial walls have all been
reported following chronic lead exposure (16,19,20).
Cardiac Effects of Lead in Humans
Case-based reports that have appeared in the clinical
literature during the last three decades have presented
rather compelling evidence attesting to the nature andKOPP, BARRON, AND TOW
extent of the cardiac complications that develop in
humans in response to chronic and acute lead poison-
ing (21-26). Myocarditis (21,22), electrocardiographic
abnormalities (16,23,24), altered heart rate activity
(16,24), slowed ventricular systole (16,25), hyperten-
sion (16,26-29), and vascular degeneration (16,22)
have all been among the reported cardiovascular
aberrations detected in humans chronically and
acutely exposed to toxic lead levels (Table 1). Although
the threshold blood lead level that triggers cardiac
involvement and symptoms of cardiotoxicity has not
been determined conclusively, it is apparent that envi-
ronmental and occupational lead exposures that raise
blood lead levels above 100 ,ug% and 60 gg% in adults
and children, respectively, are frequently associated
with transient as well as permanent cardiac and vas-
cular lesions and functional disturbances (21-29). At
lower blood levels the effects of lead on the heart and
vasculature have not been firmly established. The pos-
sibility exists, based on recent epidemiologic findings,
that lead may induce adverse cardiovascular effects
(i.e., hypertension) at blood levels commonly found in
the general, nonoccupationally exposed population
(1-3,29,30). The postulated causal association between
lead and hypertension remains a subject of consider-
able debate and controversy (1-3,16,27-34).
Clinical evidence suggesting that lead poisoning
may induce cardiac disturbances symptomatic of
myocarditis was first reported by Read and Williams
(21). Shortly thereafter, Kline (22) presented histo-
logical findings that unequivocally characterized the
degenerative and inflammatory changes in the myo-
cardium that occurred in conjunction with chronic
lead poisoning. This latter study involved five chil-
dren ages 12 to 26 months who died of complications of
acute lead poisoning. Three of these deaths were
attributed to heart failure secondary to chronic myo-
carditis. Lead poisoning has also been shown in these
and other studies to cause significant disturbances in
the electrical activity of the heart (16,23,24). Electro-
cardiographic abnormalities, including sinus bra-
dycardia (21,23-25), multifocal ventricular escape
beats (21), T-wave inversion (24), left bundle branch
block (LBBB) (21), first degree heart block (16,23), and
ectopic atrial rhythms (24) have all been reported in
conjunction with chronic lead poisoning. Chelation
therapy generally has been shown to reverse these dis-
turbances; however, instances of permanent damage
have also been reported (Table 1) (24).
Other cardiac and vascular complications linked to
excessive lead exposure in occupationally exposed
workers have also been reported. These effects, which
have been summarized in reviews by Stofen (16),
include abnormally low voltage waves (P and T waves)
in the ECG, S-T interval changes, arteriosclerotic
changes characterized by vascular degeneration, inti-
mal fatty infiltration and proliferation of perivascular
connective tissue, and reduced physical work en-
durance and abnormal cardiovascular responses to
exercise. These latter effects are remarkably similar to
Table 1. Cardiotoxic manifestations of environmental
lead in humans.
Group; Reported
Blood lead, pg0/o disturbances Reference
Lead worker
NRa
Children died
from complications
ofacute lead
poisoning: 3/5 cause
ofdeath attributed
to heart failure
secondary to
chronic myo-
carditis, NR
Lead workers,
> 100
Children, > 60
Lead workers,
NR
Adult, > 250
Bradycardia, LBBB,
multifocal ventricular
escape beats, myocarditis
Autopsy findings:
Myocarditis-muscle
fiber degeneration,
interstitial edema;
connective tissue
infiltration, compres-
sion and replacement
ofadjacent muscle
fibers
A-V conduction
disturbances; 1° HB;
ectopic atrial rhythms
Atrial arrhythmias
(5/30; rev4/5)
Abnormal PR interval
(6/30; rev 5/6)
QT, interval prolonged
(15/30; rev 15/15)
Inverted Twave
(5/30; rev 4/5)
Bradycardia, shorter
ventricular ejection
time, prolonged
ventricular contrac-
tion time
Impaired 3-receptor-
mediated cardiovas-
cular function:
THeart rate at maxi-
mum physical work
capacity
4IChronotropic
responsiveness
to isoproternol
(12-fold dose)
THeart rate by 25
beats
4IPlasma renin
activity (1/10 of
control)
(21)
(22)
(23)
(24)
(25)
(26)
aNR, not reported.
those described by Bertel and co-workers (26).
According to the findings reported by Bertel et al.
(26), the abnormal cardiovascular responses to exercise
may emanate from a lead-induced defect in systemic ,B-
adrenergic receptor function. Severe lead intoxication
was associated in the Bertel study with a suppression of
plasma renin activity, an exaggerated blood pressure
but truncated heart rate response to exercise, an in-
crease in plasma norepinephrine levels, and a marked
attenuation of the positive chronotropic response to
catecholamine (isoproterenol) stimulation. Collec-
tively, these results were interpreted by these authors to
indicate that excessive blood lead levels may have
caused a generalized desensitization of 3-adrenergic
receptors, which depressed the normal circulatory
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adjustments to exercise (e.g., decreased peripheral vas-
cular resistance, tachycardia). As a consequence, blood
pressure regulation was altered in the case studied,
leading to hypertensive episodes under basal and
exercise-stress conditions. This observation is note-
worthy in that it suggests a possible mechanism for
the transient hypertension reported in cases of lead
intoxication(16,26), and it may also play a role in the
blood pressure effects of lead following lower dose
exposures commonly encountered by the general
population (1-3, 28-30).
Although the heart and vasculature are generally
not regarded as primary target sites for lead in
mammalian systems, it is readily apparent from the
foregoing summary that human lead poisoning can
lead to overt, clinical symptoms of heart disease. Myo-
cardial contractile function, excitability, and respon-
siveness to P-adrenergic receptor stimulation have all
been reported to be affected by lead in these cases.
Depending on the dose and the duration of the lead
exposure, the cardiac and vascular complications and
the damage that results are potentially life threatening.
Less certain are the cardiovascular effects of lead at
lower exposure levels. Until recently, the pluricausal
nature of heart and vascular diseases combined with
their generally slow progression before clinical symp-
toms develop have confounded attempts to identify
what, if any, effect low-level lead exposure may have on
the human cardiovascular system. Recent epidemio-
logical findings, however, have provided strong sup-
port for the hypothesis that lead may be a contributing
pathogenic factor in human essential hypertension
(1-3). Although still controversial, positive correla-
tions between blood lead levels and systemic arterial
pressure have been repeatedly reported in these epide-
miologic studies. The relationship reported indicates
that blood pressure varies as a direct function of the
blood lead concentration at levels commonly encount-
ered in the average population. Thus, it is conceivable
that lead may induce adverse cardiovascular effects in
humans at levels well below those previously reported
to induce overt, toxic manifestations. Further studies,
particularly ones that provide a more sensitive indi-
cation oflead exposure than that provided by blood lead
levels, are needed before this and other issues relating
to the human health effects oflead can be resolved.
Cardiac Effects of Lead in
Experimental Animals
Generally, chronic administration of lead to exper-
imental animals has been shown to cause adverse car-
diovascular changes similar to those reported in
humans (4,6,14,17-20,35-44). As illustrated in Fig-
ure 1, diverse cardiovascular effects have been detected
over a wide range of oral lead doses of varying dura-
tion. Unfortunately, as noted in Figure 1, blood lead
levels were reported in relatively few ofthese studies. As
a consequence, the only basis for comparing the results
obtained in these different studies appears to be in
terms of the dose of lead administered. Not surpris-
ingly, the extent of the cardiac and vascular involve-
ment appears to escalate as a direct function of the oral
lead dose. In general, administration of lead, most
commonly as the acetate salt, to experimental animals
has been shown to induce myocarditis (42), degen-
erative structural and biochemical changes affecting
the musculature of the heart and vasculature
(35,37,42,43), hypertension (4,6,14,38-40), hyper-
cholesterolemia (6,16,19,20), increased arterial plaque
deposition (19,20), electrocardiographic disturbances
(38,39), accentuated catecholamine-arrhythmogen-
icity (5,17,41), altered contractile responsiveness of the
myocardium to inotropic stimulation (44), and in-
creased vascular reactivity to a-adrenergic agonists
(5,17,41,44). Although incomplete, recent evidence
suggests a role for calcium in the chronic and acute
toxicity of lead in the cardiovascular system (6). Per-
haps the most noteworthy association between these
metals is that involving the direct cardiotoxic actions
oflead (10).
Contractile and Metabolic Actions
The most severe myocardial damage attributed to
chronic lead exposure has been reported in studies that
have used lead doses that are overtly toxic (37,42,43).
Diffuse, degenerative structural changes in the myo-
cardium suggestive of myocarditis have been reported
by Asokan following acute, oral lead administration
(approximately, 6.5 mg/mL drinking fluid) for 6
weeks (42). Similar morphologic abnormalities,
however, have been described by Moore and co-workers
(43) in rats receiving a 60-fold lower dose than that
used by Asokan for 25 weeks. These investigators also
reported a significant decline in enzyme (heme
synthetase and aminolaevulinic dehydratase) activ-
ities in conjunction with this level and duration of
lead exposure.
Administration of lead to isolated heart preparations
at effective doses appears to induce cardiotoxic man-
ifestations similar to those reported in conjunction
with lead poisoning in vivo. As such, this experimental
approach has been used to more thoroughly charac-
terize the cardiotoxic actions of lead. In these latter
studies, lead has been consistently shown to induce a
profound depression of myocardial contractile func-
tion, electromechanical dissociation, and marked dis-
turbances in myocardial energy metabolism (10,44).
The magnitude of these effects has been shown to
depend on the extracellular calcium levels; below 3.5
mM, calcium antagonizes the cardiotoxic effects oflead;
5.0 mM calcium exacerbates the lead effects. This latter
observation suggests that the increased metabolic
demand placed on the heart by elevated extracellular
calcium levels may increase the vulnerability of the
heartto lead.
Subsequent studies focusing on the mechanistic
basis for the contractile dysfunction induced by lead in
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FIGURE 1. Representative spectrum ofreported cardiovascular effects oflead in experimental animals as a function oforal lead dose. As noted in the
left-hand column, the duration oflead administration, which varied considerably among the different studies, is noted for each study in days (da.)
in the left-hand column. The lead salt administered and the reported blood lead level (pg%) are listed in the reference column.
the heart and the corresponding disturbances in
myocardial energy metabolism support this inter-
pretation. In these studies it has been possible to deter-
mine that the negative inotropic actions of lead are
linked to disturbances in mitochondrial and sarco-
plasmic proton gradients (Fig. 2). These effects, which
were most pronounced in hearts perfused with lead (30
,uM) in combination with 5 mM calcium, were fol-
lowed by a time-dependent decline in cellular high-
energy phosphate (primarily ATP) stores and con-
tractile performance. These findings have been inter-
preted as a lead-induced inhibition of mitochondrial
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FIGuRE 2. Left panel: selected, sequential intact heart 31P NMR spectra of a 30 pM Pb-perfused rat heart illustrating the emergence of multiple,
intracellular acidic pools of inorganic phosphate (Pi) and the progressive decline in cellular high energy phosphate stores, principally ATP. The
dashed lines are a visual aid to follow the plot-offshift ofthe sequentially plotted spectra. Right panel: 31P NMR spectrum ofthe tissue perchloric
acid extract prepared from the heart shown in the left panel. Heart was immediately frozen by compression in liquid N2-chilled Wollenberger
clamps at the conclusion of the experiment and subsequently acid-extracted under cryogenic conditions. PCr, phosphocreatine; ATP, adenosine
triphosphate with respective g, a, and b phosphorus resonance signals.
respiration, which perturbs intracellular proton
gradients and leads to impaired energy metabolism
(44,45). The depressed contractile function of lead-
treated hearts thus appears to emanate initially from
the effects of lead on intracellular proton gradients,
which is then aggravated by the progressive loss of
cellular ATP stores. There was no evidence obtained by
the 31p NMR spectroscopic procedures used in this
study (45) that indicated that lead altered the avail-
ability of ATP by forming a lead-ATP complex. This
interpretation suggesting a mitochondrial site of
action of lead in the intact heart is consistent with the
reported actions of lead on isolated heart mitochondria
(46).
Significant cardiac effects have also been detected
following administration of lower, oral doses of lead
(4,5,9,14,18-20,38-41). Certain ofthese effects are sim-
ilar to those observed in the isolated heart studies,
while other effects are not. Myocardial contractile per-
formance measured under ex vivo conditions in hearts
from rats administered lead (5 ,ug/mL drinking
water) for 20 months was shown to be depressed
significantly (38,39). This effect of lead was linked to
disturbances in myocardial energy metabolism and
defective phosphorylation of putative regulatory
phosphoproteins suspected of being involved in the
regulation of chemicomechanical energy transduc-
tion in heart muscle (38,47,48).
In contrast, in vivo measures of myocardial con-
tractile activity (44) performed in rats following 12
months of oral exposure to lead (1 ,ug/mL drinking
water) have revealed a heightened contractile response
of the myocardium to norepinephrine (6 x 10-1 I
mole/kg body weight) without evidence of depressed
function under basal conditions. This relationship is
illustrated in Figure 3, which depicts the dose-depen-
dent effects of norepinephrine on the maximal rate of
change in left ventricular pressure development
(+dP/dt). This effect appeared to be a compensatory
response for the effect of lead on myocardial outflow
resistance, as evidenced by the increased aortic after-
load detected in these animals (Fig. 4).
Intraventricular pulse pressure and heart rate
responses were not affected by lead treatment. The dur-
ation of the positive inotropic response to norepi-
nephrine was prolonged significantly at the two
highest norepinephrine concentrations, suggesting
an increased norepinephrine half-life in the lead-
treated rats relative to the control group. The para-
doxical findings obtained in these studies suggest that
prior lead treatment significantly alters the capacity of
the heart to function under experimentally imposed
conditions (i.e., ex vivo perfusion versus in vivo con-
ditions). It is conceivable that the cardiodepressive
effects of lead following relatively low prior exposure
are unmasked under ex vivo conditions due to the
elimination of neural and hormonal influences on
the heart.
Effects on Cardiac Excitability
As described earlier, clinical evidence exists sug-
gesting that lead may also affect the electrical stability
and excitability of the heart (16,23,24). It has been pos-
tulated that these disturbances result from effects oflead
on the parasympathetic and sympathetic nerves in-
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FIGURE 3. In vivo myocardial contractile performance as measured by the rate ofchange in left ventricular pressure development (+dP/dt), shown
as a function of IV norepinephrine (NE) dose in rats that received either control or lead-containing (1 pg Pb/mL) drinking water for 12 months.
The graph illustrates the increased responsiveness of hearts in lead-treated rats that occurred in response to the lowest, and perhaps the most
physiologically relevant dose of norepinephrine administered. The inset graph presents essentially the same relationship in relative terms as
percent change in contractile performance. Values represent mean ± SE for 10 rats per group; asterisk (*) p < 0.05.
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FIGURE 4. In vivo aortic afterload as a function of IV norepinephrine
dose in the same groups ofrats described in Fig. 3. In thisfigure aor-
tic afterload corresponds to aortic diastolic pressure just prior to the
onset of ventricular ejection. Although not shown, ventricular pulse
pressure during ventricular ejection was significantly higher at the
lower norepinephrine doses in the lead-treated rats as compared to
the control group. Values correspond to mean ± SE for 10 rats per
group; asterisk (*) p < 0.05.
nervating the heart. The reported electrocardiographic
findings (e.g., bradycardia, heart block, slowed sinus
rate with ventricular escape beats) are consistent with
the interpretation that vagal tone on the heart is
increased (49). This action of lead has been studied,
though not extensively, at the level of the intact animal
and in the isolated heart. Oral administration of lead
(5 ,ug/mL drinking water) for 15 and 20 months has
been reported to be associated with a significant slow-
ing of atrioventricular conduction, as evidenced by
prolongation of the P-R interval in the ECG (39). This
effect was localized in these studies to the His-Purkinje
system by His bundle electrocardiographic analysis.
Atrioventricular node excitability (A-H interval), Q-S
interval, and heart rate were not affected significantly
by lead treatment. These in vivo effects of lead generally
parallel those reported in isolated perfused rat heart
studies (8,10). The ability of lead to depress atrioven-
tricular conduction in the intact, denervated rat heart
suggests that the reported effects of lead on cardiac
excitability may involve direct actions in addition to
the postulated neurally mediated mechanisms. The
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susceptibility of the heart to ischemia- and catecho-
lamine-induced arrhythmias (ectopic ventricular
extrasystoles) has also been shown to be affected by
chronic lead exposure (5,17,41). These effects have been
demonstrated both in adult rats exposed to lead as
neonates (5) and in adult rats exposed to lead (5 or 25
,ug/mL drinking water) since weaning for 12 to 16
months (41). Overall, the reported actions of lead on
myocardial excitability are indicative of possible lead-
induced disturbances in cell membrane function and
ion conductance. Further studies are needed to iden-
tify the membrane sites affected by the action oflead.
Vascular Actions
As illustrated in Figure 1, the most pervasive, and
perhaps most controversial, effect of lead is its apparent
effect on systemic blood pressure following chronic oral
administration. The pressor effect of lead has been
demonstrated over a wide range of lead doses (4,18,20,
36,39,40). The mechanistic basis for this effect has
eluded discovery. It is apparent from the foregoing
summary that the pressor effect of lead is not likely
cardiac in origin. Instead, Webb (14) and others (11-
13,15,18) have provided evidence implicating vascu-
lar sites of action. Increased in vivo vascular reactivity
to a-adrenergic agonists has been reported in lead-
treated rats following 7 months ofexposure (14).
In addition, lead has been shown to directly induce
arterial smooth muscle contraction in potassium-de-
polarized vascular preparations incubated with and
without calcium (12,13,15). Recent studies performed
in our laboratories have demonstrated lead adminis-
tration to helical carotid artery strips causes an in-
crease in basal contractile tone of vascular smooth
muscle but does not significantly alter the maximal
tension elicited by norepinephrine (Fig. 5). Vessels
were mounted in a constant temperature (370C) mus-
cle chamber and equilibrated for 2 hr prior to Pb treat-
ment in a standard physiological salt solution (PSS)
aerated with 95% 02 and 5% CO2 (pH 7.4). Passive ten-
sion sufficient to simulate 100 mm Hg mean arterial
pressure was applied to each preparation. Following
equilibration, the functional integrity of each vessel
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FIGURE 5. The effect oflead on the contractile function [tension and percent maximum tension (inset)] produced by isolated vascular smooth muscle
strips (helically cut porcine carotid artery) in response to various norepinephrine doses. This experiment was conducted according to standard
procedures (50).Values presented represent means ± SE of a minimum ofsix differentvessels; asterisk (*) p < 0.01.
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was assessed: tension capacity, response to 5 x 10-6 M
norepinephrine; endothelial integrity, response to 1 x
10-5 M acetylcholine. Abnormally responding vessels
were discarded; the remainder were incubated in
either control or Pb-containing PSS for 1.5 hr and
subsequently treated with norepinephrine at the doses
indicated. Collectively, these in vitro observations sup-
port the mechanism proposed by Piccinini and co-
workers (13), which asserts that lead inhibits cellular
calcium extrusion, thereby increasing the intracel-
lular concentration of calcium available to support
contraction-coupling processes. It is conceivable that
similar effects of lead in vivo may contribute to the re-
ported pressor effects and enhanced vascular reactivity
observed in rats subjected to chronic lead adminis-
tration.
Concluding Remarks
Lead poisoning unequivocally results in significant
derangements in cardiovascular function in humans
and experimental animals. The cardiotoxic manifes-
tations include depression of myocardial contractile
activity, electrical disturbances, and tissue metabolic
damage. The degree of cardiac involvement during
episodes of lead intoxication appears to depend on the
level and duration of exposure. Less certain are the
effects of subclinical lead exposures on the cardiovas-
cular system. As summarized, chronic low-level lead
exposure has been shown to affect the electrical and
mechanical activity of the heart and to alter vascular
smooth muscle function in experimental animals.
Whether lead produces similar effects in humans is
unknown; however, recent findings suggest that lead
may play a role in human essential hypertension.
Further studies are needed that will more completely
characterize the cardiovascular effects oflow lead expo-
sure, identify the factors that predispose the heart and
vasculature to the actions of lead, and define the cellu-
lar and subcellular mechanisms through which lead
acts to disturb the normal function and regulation of
the cardiovascular system.
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